Higher grade transformation of follicular lymphoma: Phenotypic tumor progression associated with diverse genetic lesions

Seminars in Cancer Biology

Volumn 13, Issue 3, 2003, Pages 191-202

  Lossos, Izidore S ^a   Levy, Ronald ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C MYC; Diffuse large B cell lymphoma; Follicle center lymphoma; Molecular changes; Transformation

Indexed keywords

ATM PROTEIN; FAS ANTIGEN; RAS PROTEIN;

APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION; DEREGULATION; FOLLICULAR LYMPHOMA; GENE AMPLIFICATION; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE OVEREXPRESSION; GENE REARRANGEMENT; GENE THERAPY; HUMAN; LARGE CELL LYMPHOMA; MICROSATELLITE INSTABILITY; ONCOGENE C MYC; ONCOGENE RAS; PHENOTYPE; PROTO ONCOGENE; REVIEW; TUMOR GROWTH;

EID: 0037957281     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1044-579X(03)00015-4     Document Type: Review

References (153)

1. Harris N.L., Jaffe E.S., Diebold J., Flandrin G., Muller-Hermelink H.K., Vardiman J.et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J. Clin. Oncol. 17:1999;3835-3849.
2. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K., Cleary M.L.et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 84:1994;1361-1392.
3. Rappaport H., Winter W.J., Hicks E.B. Follicular lymphoma - a reevaluation of its position in the scheme of malignant lymphoma based on a survey of 253 cases. Cancer. 9:1956;792-821.
4. Qazi R., Aisenberg A.C., Long J.C. The natural history of nodular lymphoma. Cancer. 37:1976;1923-1927.
5. Cullen M.H., Lister T.A., Brearley R.I., Shand W.S., Stansfeld A.G. Histological transformation of non-Hodgkin's lymphoma: a prospective study. Cancer. 44:1979;645-651.
6. Risdall R., Hoppe R.T., Warnke R. Non-Hodgkin's lymphoma: a study of the evolution of the disease based upon 92 autopsied cases. Cancer. 44:1979;529-542.
7. Ostrow S.S., Diggs C.H., Sutherland J.C., Gustafson J., Wiernik P.H. Nodular poorly differentiated lymphocytic lymphoma: changes in histology and survival. Cancer Treat. Rep. 65:1981;929-933.
8. Hubbard S.M., Chabner B.A., DeVita V.T., Simon R., Berard C.W., Jones R.B.et al. Histologic progression in non-Hodgkin's lymphoma. Blood. 59:1982;258-264.
9. Acker B., Hoppe R.T., Colby T.V., Cox R.S., Kaplan H.S., Rosenberg S.A. Histologic conversion in the non-Hodgkin's lymphomas. J. Clin. Oncol. 1:1983;11-16.
10. Garvin A.J., Simon R.M., Osborne C.K., Merrill J., Young R.C., Berard C.W. An autopsy study of histologic progression in non-Hodgkin's lymphomas. 192 cases from the National Cancer Institute. Cancer. 52:1983;393-398.
11. Horning S.J., Rosenberg S.A. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N. Engl. J. Med. 311:1984;1471-1475.
12. Oviatt D.L., Cousar J.B., Collins R.D., Flexner J.M., Stein R.S. Malignant lymphomas of follicular center cell origin in humans. V. Incidence, clinical features, and prognostic implications of transformation of small cleaved cell nodular lymphoma. Cancer. 53:1984;1109-1114.
13. Gallagher C.J., Gregory W.M., Jones A.E., Stansfeld A.G., Richards M.A., Dhaliwal H.S.et al. Follicular lymphoma: prognostic factors for response and survival. J. Clin. Oncol. 4:1986;1470-1480.
14. Ersboll J., Schultz H.B., Pedersen-Bjergaard J., Nissen N.I. Follicular low-grade non-Hodgkin's lymphoma: long-term outcome with or without tumor progression. Eur. J. Haematol. 42:1989;155-163.
15. Bastion Y., Sebban C., Berger F., Felman P., Salles G., Dumontet C.et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J. Clin. Oncol. 15:1997;1587-1594.
16. De Jong D., Voetdijk B.M., Beverstock G.C., van Ommen G.J., Willemze R., Kluin P.M. Activation of the c-myc oncogene in a precursor-B-cell blast crisis of follicular lymphoma, presenting as composite lymphoma. N. Engl. J. Med. 318:1988;1373-1378.
17. Gauwerky C.E., Haluska F.G., Tsujimoto Y., Nowell P.C., Croce C.M. Evolution of B-cell malignancy: pre-B-cell leukemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL2 gene. Proc. Natl. Acad. Sci. U.S.A. 85:1988;8548-8552.
18. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., Kantarjian H.M. The biology of chronic myeloid leukemia. N. Engl. J. Med. 341:1999;164-172.
19. Wetzler M., Talpaz M., Estrov Z., Kurzrock R. CML: mechanisms of disease initiation and progression. Leuk. Lymphoma. 11:1993;47-50.
20. Hainaut P., Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res. 77:2000;81-137.
21. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331.
22. Gaidano G., Ballerini P., Gong J.Z., Inghirami G., Neri A., Newcomb E.W.et al. p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 88:1991;5413-5417.
23. Koduru P.R., Raju K., Vadmal V., Menezes G., Shah S., Susin M.et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood. 90:1997;4078-4091.
24. Ichikawa A., Kinoshita T., Watanabe T., Kato H., Nagai H., Tsushita K.et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N. Engl. J. Med. 337:1997;529-534.
25. Chen P.M., Chiou T.J., Hsieh R.K., Fan F.S., Chu C.J., Lin C.Z.et al. p53 gene mutations and rearrangements in non-Hodgkin's lymphoma. Cancer. 85:1999;718-724.
26. Lo Coco F., Gaidano G., Louie D.C., Offit K., Chaganti R.S., Dalla-Favera R. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood. 82:1993;2289-2295.
27. Sander C.A., Yano T., Clark H.M., Harris C., Longo D.L., Jaffe E.S.et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 82:1993;1994-2004.
28. Symmans W.F., Katz R.L., Ordonez N.G., Dalton H., Romaguera J.E., Cabanillas F. Transformation of follicular lymphoma. Expression of p53 and bcl-2 oncoprotein, apoptosis and cell proliferation. Acta Cytol. 39:1995;673-682.
29. Obaya A.J., Mateyak M.K., Sedivy J.M. Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene. 18:1999;2934-2941.
30. Cole M.D., McMahon S.B. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene. 18:1999;2916-2924.
31. Schmidt E.V. The role of c-myc in cellular growth control. Oncogene. 18:1999;2988-2996.
32. Prendergast G.C. Mechanisms of apoptosis by c-Myc. Oncogene. 18:1999;2967-2987.
33. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene. 18:1999;3004-3016.
34. Adams J.M., Harris A.W., Pinkert C.A., Corcoran L.M., Alexander W.S., Cory S.et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 318:1985;533-538.
35. Felsher D.W., Bishop J.M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 96:1999;3940-3944.
36. Boxer L.M., Dang C.V. Translocations involving c-myc and c-myc function. Oncogene. 20:2001;5595-5610.
37. Bahram F., von der Lehr N., Cetinkaya C., Larsson L.G. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 95:2000;2104-2110.
38. Raffeld M., Yano T., Hoang A.T., Lewis B., Clark H.M., Otsuki T.et al. Clustered mutations in the transcriptional activation domain of Myc in 8q24 translocated lymphomas and their functional consequences. Curr. Top. Microbiol. Immunol. 194:1995;265-272.
39. Hoang A.T., Lutterbach B., Lewis B.C., Yano T., Chou T.Y., Barrett J.F.et al. A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol. Cell Biol. 15:1995;4031-4042.
40. Pulverer B.J., Fisher C., Vousden K., Littlewood T., Evan G., Woodgett J.R. Site-specific modulation of c-Myc cotransformation by residues phosphorylated in vivo. Oncogene. 9:1994;59-70.
41. Henriksson M., Bakardjiev A., Klein G., Luscher B. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene. 8:1993;3199-3209.
42. Rao P.H., Houldsworth J., Dyomina K., Parsa N.Z., Cigudosa J.C., Louie D.C.et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood. 92:1998;234-240.
43. Ladanyi M., Offit K., Parsa N.Z., Condon M.R., Chekka N., Murphy J.P.et al. Follicular lymphoma with t(8;14)(q24;q32): a distinct clinical and molecular subset of t(8;14)-bearing lymphomas. Blood. 79:1992;2124-2130.
44. Offit K., Wong G., Filippa D.A., Tao Y., Chaganti R.S. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood. 77:1991;1508-1515.
45. Yunis J.J., Mayer M.G., Arnesen M.A., Aeppli D.P., Oken M.M., Frizzera G. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N. Engl. J. Med. 320:1989;1047-1054.
46. Yano T., Jaffe E.S., Longo D.L., Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood. 80:1992;758-767.
47. Lee J.T., Innes D.J. Jr., Williams M.E. Sequential bcl-2 and c-myc oncogene rearrangements associated with the clinical transformation of non-Hodgkin's lymphoma. J. Clin. Invest. 84:1989;1454-1459.
48. Arcinas M., Heckman C.A., Mehew J.W., Boxer L.M. Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma. Cancer Res. 61:2001;5202-5206.
49. Strasser A., Harris A.W., Bath M.L., Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature. 348:1990;331-333.
50. Marin M.C., Hsu B., Stephens L.C., Brisbay S., McDonnell T.J. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo. Exp. Cell Res. 217:1995;240-247.
51. Lossos I.S., Alizadeh A.A., Diehn M., Warnke R., Thorstenson Y.R., Oefner P. Transformation of follicular lymphoma to diffuse large cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc. Natl. Acad. Sci. U.S.A. 99:2002;8886-8891.
52. Arranz E., Martinez B., Richart A., Echezarreta G., Roman A., Rivas C.et al. Increased C-MYC oncogene copy number detected with combined modified comparative genomic hybridization and FISH analysis in a Richter syndrome case with complex karyotype. Cancer Genet. Cytogenet. 106:1998;80-83.
53. Martinez-Climent J.A., Alizadeh A.A., Segraves R., Blesa D., Rubio-moscardo F., Alberrson D.G., Garcia Conde J., Dyer M.J., Levy R., Pinkel D., Lossos I.S. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with heterogeneous set of DNA copy number and gene expression alterations. Blood. 101(8):2003;3109-3117.
54. Serrano M., Hannon G.J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 366:1993;704-707.
55. Serrano M., Lee H., Chin L., Cordon-Cardo C., Beach D., DePinho R.A. Role of the INK4a locus in tumor suppression and cell mortality. Cell. 85:1996;27-37.
56. Drexler H.G. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 12:1998;845-859.
57. Herman J.G., Civin C.I., Issa J.P., Collector M.I., Sharkis S.J., Baylin S.B. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 57:1997;837-841.
58. Gronbaek K., Nedergaard T., Andersen M.K., thor Straten P., Guldberg P., Moller P.et al. Concurrent disruption of cell cycle associated genes in mantle cell lymphoma: a genotypic and phenotypic study of cyclin D1, p16, p15, p53 and pRb. Leukemia. 12:1998;1266-1271.
59. Baur A.S., Shaw P., Burri N., Delacretaz F., Bosman F.T., Chaubert P. Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood. 94:1999;1773-1781.
60. Pinyol M., Cobo F., Bea S., Jares P., Nayach I., Fernandez P.L.et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood. 91:1998;2977-2984.
61. Elenitoba-Johnson K.S., Gascoyne R.D., Lim M.S., Chhanabai M., Jaffe E.S., Raffeld M. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood. 91:1998;4677-4685.
62. Villuendas R., Sanchez-Beato M., Martinez J.C., Saez A.I., Martinez-Delgado B., Garcia J.F.et al. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression. Am. J. Pathol. 153:1998;887-897.
63. Chang C.C., Ye B.H., Chaganti R.S., Dalla-Favera R. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc. Natl. Acad. Sci. U.S.A. 93:1996;6947-6952.
64. Kerckaert J.P., Deweindt C., Tilly H., Quief S., Lecocq G., Bastard C. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nat. Genet. 5:1993;66-70.
65. Seyfert V.L., Allman D., He Y., Staudt L.M. Transcriptional repression by the proto-oncogene BCL-6. Oncogene. 12:1996;2331-2342.
66. Cattoretti G., Chang C.C., Cechova K., Zhang J., Ye B.H., Falini B.et al. BCL-6 protein is expressed in germinal-center B cells. Blood. 86:1995;45-53.
67. Ye B.H., Cattoretti G., Shen Q., Zhang J., Hawe N., de Waard R.et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat. Genet. 16:1997;161-170.
68. Chaganti S.R., Chen W., Parsa N., Offit K., Louie D.C., Dalla-Favera R.et al. Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer. 23:1998;323-327.
69. Ye B.H., Lista F., Lo Coco F., Knowles D.M., Offit K., Chaganti R.S.et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science. 262:1993;747-750.
70. Lo Coco F., Ye B.H., Lista F., Corradini P., Offit K., Knowles D.M.et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood. 83:1994;1757-1759.
71. Bastard C., Deweindt C., Kerckaert J.P., Lenormand B., Rossi A., Pezzella F.et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood. 83:1994;2423-2427.
72. Ye B.H., Chaganti S., Chang C.C., Niu H., Corradini P., Chaganti R.S.et al. Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma. EMBO J. 14:1995;6209-6217.
73. Chen W., Iida S., Louie D.C., Dalla-Favera R., Chaganti R.S. Heterologous promoters fused to BCL6 by chromosomal translocations affecting band 3q27 cause its deregulated expression during B-cell differentiation. Blood. 91:1998;603-607.
74. Szereday Z., Csernus B., Nagy M., Laszlo T., Warnke R.A., Matolcsy A. Somatic mutation of the 5′ noncoding region of the BCL-6 gene is associated with intraclonal diversity and clonal selection in histological transformation of follicular lymphoma. Am. J. Pathol. 156:2000;1017-1024.
75. Akasaka T., Lossos I.S., Levy R. Analysis of BCL6 gene translocations in higher grade transformation of follicle center lymphomas (FCL). Blood. 98:2001;330a.
76. Migliazza A., Martinotti S., Chen W., Fusco C., Ye B.H., Knowles D.M.et al. Frequent somatic hypermutation of the 5′ noncoding region of the BCL6 gene in B-cell lymphoma. Proc. Natl. Acad. Sci. U.S.A. 92:1995;12520-12524.
77. Pasqualucci L., Migliazza A., Fracchiolla N., William C., Neri A., Baldini L.et al. BCL-6 mutations in normal germinal center B cells: evidence of somatic hypermutation acting outside Ig loci. Proc. Natl. Acad. Sci. U.S.A. 95:1998;11816-11821.
78. Bernardin F., Collyn-d'Hooghe M., Quief S., Bastard C., Leprince D., Kerckaert J.P. Small deletions occur in highly conserved regions of the LAZ3/BCL6 major translocation cluster in one case of non-Hodgkin's lymphoma without 3q27 translocation. Oncogene. 14:1997;849-855.
79. Lossos I.S., Levy R. Mutation analysis of the 5′ noncoding regulatory region of the BCL-6 gene in non-Hodgkin lymphoma: evidence for recurrent mutations and intraclonal heterogeneity. Blood. 95:2000;1400-1405.
80. Peng H.Z., Du M.Q., Koulis A., Aiello A., Dogan A., Pan L.X.et al. Nonimmunoglobulin gene hypermutation in germinal center B cells. Blood. 93:1999;2167-2172.
81. Capello D., Vitolo U., Pasqualucci L., Quattrone S., Migliaretti G., Fassone L.et al. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia. Blood. 95:2000;651-659.
82. Shen H.M., Peters A., Baron B., Zhu X., Storb U. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science. 280:1998;1750-1752.
83. Pasqualucci L., Migliazza A., Ye B., Cattoretti G., Chaganti R., Dalla-Favera R. Transcriptional deregulation of mutated BCL-6 alleles in diffuse large cell lymphomas. Blood. 94:1999;58a.
84. Lossos I.S., Warnke R., Levy R. BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: correlation with somatic mutations in the 5' regulatory region of the BCL-6 gene. Leukemia. 16(9):2002;1857-1862.
85. Lossos I.S., Levy R. Higher grade transformation of follicle center lymphoma is associated with somatic mutation of the 5′ noncoding regulatory region of the BCL-6 gene. Blood. 96:2000;635-639.
86. Tsujimoto Y., Cossman J., Jaffe E., Croce C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science. 228:1985;1440-1443.
87. Tsujimoto Y., Gorham J., Cossman J., Jaffe E., Croce C.M. The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science. 229:1985;1390-1393.
88. Cleary M.L., Galili N., Sklar J. Detection of a second (t14;18) breakpoint cluster region in human follicular lymphomas. J. Exp. Med. 164:1986;315-320.
89. Cleary M.L., Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc. Natl. Acad. Sci. U.S.A. 82:1985;7439-7443.
90. Raghoebier S., Broos L., Kramer M.H., van Krieken J.H., Kluin-Nelemans J.C., van Ommen G.J.et al. Histological conversion of follicular lymphoma with structural alterations of t(14;18) and immunoglobin genes. Leukemia. 9:1995;1748-1755.
91. Matolcsy A., Casali P., Warnke R.A., Knowles D.M. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood. 88:1996;3937-3944.
92. Reed J.C., Tanaka S. Somatic point mutations in the translocated bcl-2 genes of non-Hodgkin's lymphomas and lymphocytic leukemias: implications for mechanisms of tumor progression. Leuk. Lymphoma. 10:1993;157-163.
93. Bentz M., Werner C.A., Dohner H., Joos S., Barth T.F., Siebert R.et al. High incidence of chromosomal imbalances and gene amplifications in the classical follicular variant of follicle center lymphoma. Blood. 88:1996;1437-1444.
94. Nagy M., Balazs M., Adam Z., Petko Z., Timar B., Szereday Z.et al. Genetic instability is associated with histological transformation of follicle center lymphoma. Leukemia. 14:2000;2142-2148.
95. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49:1989;4682-4689.
96. Sprang S.R. G protein mechanisms: insights from structural analysis. Annu. Rev. Biochem. 66:1997;639-678.
97. Wittinghofer A. Signal transduction via Ras. Biol. Chem. 379:1998;933-937.
98. Janssen J.W., Steenvoorden A.C., Lyons J., Anger B., Bohlke J.U., Bos J.L.et al. RAS gene mutations in acute and chronic myelocytic leukemias chronic myeloproliferative disorders, and myelodysplastic syndromes. Proc. Natl. Acad. Sci. U.S.A. 84:1987;9228-9232.
99. Bos J.L., Verlaan-de Vries M., van der Eb A.J., Janssen J.W., Delwel R., Lowenberg B.et al. Mutations in N-ras predominate in acute myeloid leukemia. Blood. 69:1987;1237-1241.
100. Padua R.A., Carter G., Hughes D., Gow J., Farr C., Oscier D.et al. RAS mutations in myelodysplasia detected by amplification oligonucleotide hybridization and transformation. Leukemia. 2:1988;503-510.
101. Toksoz D., Farr C.J., Marshall C.J. Ras genes and acute myeloid leukaemia. Br. J. Haematol. 71:1989;1-6.
102. Kalakonda N., Rothwell D.G., Scarffe J.H., Norton J.D. Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation. Blood. 98:2001;1555-1560.
103. Neri A., Knowles D.M., Greco A., McCormick F., Dalla-Favera R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc. Natl. Acad. Sci. U.S.A. 85:1988;9268-9272.
104. Clark H.M., Yano T., Sander C., Jaffe E.S., Raffeld M. Mutation of the ras genes is a rare genetic event in the histologic transformation of follicular lymphoma. Leukemia. 10:1996;844-847.
105. Oehm A., Behrmann I., Falk W., Pawlita M., Maier G., Klas C.et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 267:1992;10709-10715.
106. Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
107. Nagata S., Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
108. Martinez-Valdez H., Guret C., de Bouteiller O., Fugier I., Banchereau J., Liu Y.J. Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2. J. Exp. Med. 183:1996;971-977.
109. Muschen M., Re D., Jungnickel B., Diehl V., Rajewsky K., Kuppers R. Somatic mutation of the CD95 gene in human B cells as a side-effect of the germinal center reaction. J. Exp. Med. 192:2000;1833-1840.
110. Muschen M., Warskulat U., Beckmann M.W. Defining CD95 as a tumor suppressor gene. J. Mol. Med. 78:2000;312-325.
111. Watanabe-Fukunaga R., Brannan C.I., Copeland N.G., Jenkins N.A., Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature. 356:1992;314-317.
112. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I.A., Debatin K.M., Fischer A.et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 268:1995;1347-1349.
113. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A., Lin A.Y.et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 81:1995;935-946.
114. Beltinger C., Kurz E., Bohler T., Schrappe M., Ludwig W.D., Debatin K.M. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood. 91:1998;3943-3951.
115. Tamiya S., Etoh K., Suzushima H., Takatsuki K., Matsuoka M. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood. 91:1998;3935-3942.
116. Landowski T.H., Qu N., Buyuksal I., Painter J.S., Dalton W.S. Mutations in the Fas antigen in patients with multiple myeloma. Blood. 90:1997;4266-4270.
117. Gronbaek K., Straten P.T., Ralfkiaer E., Ahrenkiel V., Andersen M.K., Hansen N.E.et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood. 92:1998;3018-3024.
118. Lossos I.S., Do B., Thorstenson Y.R., Oefner P., Levy R. Analysis of FAS (CD95) gene mutations in higher grade transformation of follicle center lymphoma (FCL). Blood. 98:2001;332a.
119. Khanna K.K. Cancer risk and the ATM gene: a continuing debate. J. Natl. Cancer Inst. 92:2000;795-802.
120. Morrell D., Cromartie E., Swift M. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J. Natl. Cancer Inst. 77:1986;89-92.
121. Morrell D., Chase C.L., Swift M. Cancers in 44 families with ataxia-telangiectasia. Cancer Genet. Cytogenet. 50:1990;119-123.
122. Swift M., Morrell D., Massey R.B., Chase C.L. Incidence of cancer in 161 families affected by ataxia-telangiectasia. N. Engl. J. Med. 325:1991;1831-1836.
123. Swift M., Reitnauer P.J., Morrell D., Chase C.L. Breast and other cancers in families with ataxia-telangiectasia. N. Engl. J. Med. 316:1987;1289-1294.
124. Stilgenbauer S., Schaffner C., Litterst A., Liebisch P., Gilad S., Bar-Shira A.et al. Biallelic mutations in the ATM gene in T-prolymphocytic leukemia. Nat. Med. 3:1997;1155-1159.
125. Stoppa-Lyonnet D., Soulier J., Lauge A., Dastot H., Garand R., Sigaux F.et al. Inactivation of the ATM gene in T-cell prolymphocytic leukemias. Blood. 91:1998;3920-3926.
126. Dohner H., Stilgenbauer S., James M.R., Benner A., Weilguni T., Bentz M.et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 89:1997;2516-2522.
127. Schaffner C., Stilgenbauer S., Rappold G.A., Dohner H., Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood. 94:1999;748-753.
128. Stankovic T., Weber P., Stewart G., Bedenham T., Murray J., Byrd P.J.et al. Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukaemia. Lancet. 353:1999;26-29.
129. Starostik P., Manshouri T., O'Brien S., Freireich E., Kantarjian H., Haidar M.et al. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res. 58:1998;4552-4557.
130. Bullrich F., Rasio D., Kitada S., Starostik P., Kipps T., Keating M.et al. ATM mutations in B-cell chronic lymphocytic leukemia. Cancer Res. 59:1999;24-27.
131. Schaffner C., Idler I., Stilgenbauer S., Dohner H., Lichter P. Mantle cell lymphoma is characterized by inactivation of the ATM gene. Proc. Natl. Acad. Sci. U.S.A. 97:2000;2773-2778.
132. Stilgenbauer S., Winkler D., Ott G., Schaffner C., Leupolt E., Bentz M.et al. Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. Blood. 94:1999;3262-3264.
133. Cuneo A., Bigoni R., Rigolin G.M., Roberti M.G., Milani R., Bardi A.et al. Acquired chromosome 11q deletion involving the ataxia teleangiectasia locus in B-cell non-Hodgkin's lymphoma: correlation with clinicobiologic features. J. Clin. Oncol. 18:2000;2607-2614.
134. Monni O., Zhu Y., Franssila K., Oinonen R., Hoglund P., Elonen E.et al. Molecular characterization of deletion at 11q22.1-23.3 in mantle cell lymphoma. Br. J. Haematol. 104:1999;665-671.
135. Zhu Y., Monni O., Franssila K., Elonen E., Vilpo J., Joensuu H.et al. Deletions at 11q23 in different lymphoma subtypes. Haematologica. 85:2000;908-912.
136. Lossos I.S., Thorstenson Y.R., Wayne T.L., Oefner P., Levy R., Chu G. Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher grade lymphoma. Leuk. Lymphoma. 43:2002;1079-1085.
137. Gamberi B., Gaidano G., Parsa N., Carbone A., Roncella S., Knowles D.M.et al. Microsatellite instability is rare in B-cell non-Hodgkin's lymphomas. Blood. 89:1997;975-979.
138. Richardson M.E., Chen Q.G., Filippa D.A., Offit K., Hampton A., Koduru P.R.et al. Intermediate- to high-grade histology of lymphomas carrying t(14;18) is associated with additional nonrandom chromosome changes. Blood. 70:1987;444-447.
139. Yunis J.J., Frizzera G., Oken M.M., McKenna J., Theologides A., Arnesen M. Multiple recurrent genomic defects in follicular lymphoma. A possible model for cancer. N. Engl. J. Med. 316:1987;79-84.
140. Tilly H., Rossi A., Stamatoullas A., Lenormand B., Bigorgne C., Kunlin A.et al. Prognostic value of chromosomal abnormalities in follicular lymphoma. Blood. 84:1994;1043-1049.
141. Hough R.E., Goepel J.R., Alcock H.E., Hancock B.W., Lorigan P.C., Hammond D.W. Copy number gain at 12q12-14 may be important in the transformation from follicular lymphoma to diffuse large B cell lymphoma. Br. J. Cancer. 84:2001;499-503.
142. Goff L.K., Neat M.J., Crawley C.R., Jones L., Jones E., Lister T.A.et al. The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma. Br. J. Haematol. 111:2000;618-625.
143. Bernell P., Arvidsson I., Jacobsson B. Gain of chromosome 7, which marks the progression from indolent to aggressive follicle centre lymphomas, is restricted to the B-lymphoid cell lineage: a study by FISH in combination with morphology and immunocytochemistry. Br. J. Haematol. 105:1999;1140-1144.
144. Bernell P., Jacobsson B., Liliemark J., Hjalmar V., Arvidsson I., Hast R. Gain of chromosome 7 marks the progression from indolent to aggressive follicle centre lymphoma and is a common finding in patients with diffuse large B-cell lymphoma: a study by FISH. Br. J. Haematol. 101:1998;487-491.
145. Chaganti R.S., Nanjangud G., Schmidt H., Teruya-Feldstein J. Recurring chromosomal abnormalities in non-Hodgkin's lymphoma: biologic and clinical significance. Semin. Hematol. 37:2000;396-411.
146. Matutes E., Oscier D., Garcia-Marco J., Ellis J., Copplestone A., Gillingham R.et al. Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical laboratory features in 544 patients. Br. J. Haematol. 92:1996;382-388.
147. Bea S., Ribas M., Hernandez J.M., Bosch F., Pinyol M., Hernandez L.et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood. 93:1999;4365-4374.
148. Monni O., Joensuu H., Franssila K., Knuutila S. DNA copy number changes in diffuse large B-cell lymphoma - comparative genomic hybridization study. Blood. 87:1996;5269-5278.
149. Bentz M., Barth T.F., Bruderlein S., Bock D., Schwerer M.J., Baudis M.et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer. 30:2001;393-401.
150. Cigudosa J.C., Rao P.H., Calasanz M.J., Odero M.D., Michaeli J., Jhanwar S.C.et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood. 91:1998;3007-3010.
151. Alizadeh A., Eisen M., Davis R., Ma C., Sabet H., Tran T.et al. The lymphochip: a specialized cDNA microarray for the genomic-scale analysis of gene expression in normal and malignant lymphocytes. Cold Spring Harb. Symp. Quant. Biol. 64:1999;71-78.
152. Felsher D.W., Zetterberg A., Zhu J., Tlsty T., Bishop J.M. Overexpression of MYC causes p53-dependent G2 arrest of normal fibroblasts. Proc. Natl. Acad. Sci. U.S.A. 97:2000;10544-10548.
153. Lavigueur A., Maltby V., Mock D., Rossant J., Pawson T., Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell Biol. 9:1989;3982-3991.